Spruce biosciences presented phase 2 power study results of tildacerfont for the treatment of polycystic ovary syndrome at endo 2024

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine disorders with significant unmet medical need, presented results from its phase 2 power study of tildacerfont, a second-generation crf1 receptor antagonist, for the treatment of polycystic ovary syndrome (pcos) at the 2024 annual meeting of the endocrine society (endo 2024). “there is a significant u.
SPRB Ratings Summary
SPRB Quant Ranking